{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:17:35Z","timestamp":1771715855557,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.589288","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T05:35:35Z","timestamp":1605245735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Markedly Elevated Serum Level of T-Helper Cell 17-Related Cytokines\/Chemokines in Acute Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Hao","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanping","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J Neuroinflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0149411","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"480739","DOI":"10.1155\/2013\/480739","article-title":"Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain","volume":"2013","author":"Ramesh","year":"2013","journal-title":"Mediators Inflamm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"J Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.it.2011.02.007","article-title":"IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease","volume":"32","author":"Zepp","year":"2011","journal-title":"Trends Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"Experience of the optic neuritis treatment trial. optic neuritis study group","volume":"109","year":"1991","journal-title":"Arch. Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.autrev.2014.01.009","article-title":"Diagnosis and classification of autoimmune optic neuropathy","volume":"13","author":"Petzold","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5314541","DOI":"10.1155\/2016\/5314541","article-title":"Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications","volume":"2016","author":"Dos Passos","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fimmu.2017.00311","article-title":"Immunometabolic regulation of interleukin-17-producing T helper cells: uncoupling new targets for autoimmunity","volume":"8","author":"Binger","year":"2017","journal-title":"Front Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cns.12774","article-title":"Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders","volume":"24","author":"Zhang","year":"2018","journal-title":"CNS Neurosci Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1096\/fj.09-141978","article-title":"Cellular mechanisms of IL-17-induced blood-brain barrier disruption","volume":"24","author":"Huppert","year":"2010","journal-title":"FASEB J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ni.1716","article-title":"C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE","volume":"10","author":"Reboldi","year":"2009","journal-title":"Nat Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","article-title":"Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis","volume":"234","author":"Li","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult Scler."},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaut.2014.09.003","article-title":"Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis","volume":"56","author":"Knier","year":"2015","journal-title":"J. Autoimmun."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.589288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T05:35:38Z","timestamp":1605245738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.589288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":31,"alternative-id":["10.3389\/fneur.2020.589288"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.589288","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"article-number":"589288"}}